← Back to Dashboard

Maviret

NS3/4A protease inhibitor + NS5A inhibitor

Constituent drugs (2)

Glecaprevir

Could not render structureView on PubChem
3D not available

Pibrentasvir

Could not render structureView on PubChem
3D not available

Chemical Identifiers

ClinicalTrials.govPubMed

Clinical Development by Virus1

Hepatitis C virus
HCV
Target: Viral NS3/4A + NS5A
Approved (other)
Preclinical
Phase 2positive
Phase 3positive
Approved
Japan
Approval ref (kegg.jp) Approval ref (pmda.go.jp) PMDA approved 2017/9/27fixed-dose combination of Glecaprevir, Pibrentasvir.